KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.

Atul Malhotra, Ronald R Grunstein, Ali Azarbarzin, Scott A Sands, Xiangnan Dang, Sujatro Chakladar, Julia P Dunn, Beverly Falcon, Josef Bednarik

Sleep Med 136 106853

PMID41135142
PMCIDPMC12723708
DOI10.1016/j.sleep.2025.106853
发表日期2025-10-24
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 other;Fig. 2.:AI 判定为 multi panel km;Fig. 3.:AI 判定为 other;Fig. 4.:AI 判定为 other。
摘要

摘要

BACKGROUND: Obstructive sleep apnea (OSA) is a common disorder with major cardiometabolic and neurocognitive sequelae. It affects up to 1 billion people globally and is frequently attributable to excess weight [1]. Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is FDA-approved for the treatment of moderate-to-severe OSA in adults with obesity. METHODS: The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2). The objective of these analyses was to assess time to treatment effects for improvements in apnea-hypopnea index (AHI) and sleep apnea-specific hypoxic burden (SASHB), and how these changes correspond with body weight reduction. We also aimed to investigate weight-dependent and weight-independent effects of tirzepatide treatment for OSA using linear regression analysis. RESULTS: The results of peripheral AHI (pAHI) and SASHB measurements from WatchPAT 300 in Study 1 were consistent with the polysomnographic (PSG) findings. The tirzepatide-associated improvements in pAHI were significant vs baseline as early as Week 4. However, the estimated treatment difference compared to placebo was not significant until Week 20 for both pAHI and WatchPAT-based SASHB. The magnitude of changes in AHI and SASHB were associated with achieved weight reduction in both studies. CONCLUSIONS: The results from these post hoc analyses provide details regarding the time course of resolution and insights regarding the impact of weight reduction on OSA improvements. Additional research is needed to determine the impact of body weight reduction versus other effects of tirzepatide on the improvements in OSA measures. SURMOUNT-OSA ClinicalTrials.gov number NCT05412004.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Change in AHI, pAHI, and body weight. Change from baseline in AHI (number of apneas and hypopneas events per hour of sleep) and percent change from baseline in body weight. Study 1 also includes pAHI measurements carried out with WatchPAT 300. Data points from baseline to Week 52 for Study 1 and Study 2 are shown according to the weeks since randomization, derived from a mixed-model-for-repeated-measures analysis for the efficacy estimand. Data points are LSMean ± SE. ***p < 0.001 versus placebo. AHI = apnea-hypopnea index; LSMean = least-squares mean; PBO = placebo; SE = standard error; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).
非 KM Figure
Fig. 2.Fig. 2. Sleep Apnea-Specific Hypoxic Burden (SASHB). Percentage change from baseline in SASHB. Data are geometric means (coefficient of variation, %) expressed as the time spent in event-related oxygen desaturation per hour of sleep (% min/hr). Data points from baseline to Week 52 for Study 1 and Study 2 are shown according to the weeks since randomization, derived from a mixed-model-for-repeated-measures analysis for the efficacy estimand, using Log transformation. Data points are LSMean ± SE. **p ≤ 0.010; ***p ≤ 0.001 versus placebo. LSMean = least-squares mean; PBO = placebo; SASHB = Sleep Apnea-Specific Hypoxic Burden; SE = standard error; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).
非 KM Figure
Fig. 3.Fig. 3. Percent change in AHI and SASHB by tertile analysis based on percent body weight change in participants treated with tirzepatide. Data are mean ± SD unless otherwise specified. Tertiles were based on percent body weight reduction, which was ≥22.33 % in the Upper, < 22.33 % to ≥15.65 % in the Middle, and < 15.65 % in the Lower for Study 1, and ≥23.42 % in the Upper, < 23.42 % to ≥16.23 % in the Middle, and < 16.23 % in the Lower for Study 2. AHI = apnea-hypopnea index; SASHB = sleep apnea-specific hypoxic burden; SD = standard deviation; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).
非 KM Figure
Fig. 4.Fig. 4. Linear regression analysis. Linear regression analysis demonstrating associations (A) between percent change in weight and percent change in AHI; (B) between percent change in weight and percent change in SASHB; and (C) between percent change in AHI and percent change in SASHB. For each response variable, 3 models were fit, 1 only on the participants treated with TZP, 1 only on the participants treated with placebo, and 1 on the data combined across the two treatment arms. AHI = apnea-hypopnea index; SASHB = sleep apnea-specific hypoxic burden; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).
非 KM Figure